Drug Combo Shows Benefits in Rare, Aggressive Kidney Cancer

By News Health
3 months Ago

(MedPage Today) — The combination of investigational sintilimab with axitinib (Inlyta) showed promise in patients with fumarate hydratase (FH)-deficient renal cell carcinoma (RCC), according to a phase II nonrandomized trial in China.
Among 41…

Source link : https://www.medpagetoday.com/hematologyoncology/renalcellcarcinoma/117022

Author :

Publish date : 2025-08-15 18:21:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Ocular Rosacea Underappreciated in Dermatology and Beyond

Efgartigimod Promising for Rare Pediatric Disease

Flu Antiviral Prescriptions for US Kids Plunge During COVID

Calls for legal right to paid leave for IVF treatment

Myasthenia Gravis Complement Inhibitor Meets Primary Endpoint in Phase III Trial

Medicare Finalizes Physician Fee Schedule for 2026